Return to site

Liberty Biopharma Announces Two Initial Cases for Male and Female Pattern Hair Loss, Alopecia

Liberty Biopharma Announces Two Initial Cases for Male and Female Pattern Hair Loss, Alopecia

October 18, 2016 - Richmond, British Columbia: Liberty Biopharma Inc. ("Liberty" or "Company") is pleased to announce the initial application, in two separate human cases, of its regenerative microisolate from autologous adipose tissue ("RMAAT") for male and female pattern hair loss, alopecia.

The male and female candidates that received this initial application under informed consent, have volunteered to provide continuing case pictures, on a periodic basis over the next 12 months, which the Company will publish on the website LibertyBiopharma.com.

Adipose tissue was retrieved from the patients through manual lipoaspiration and then processed within 60 minutes using Liberty's stem cell isolating bioprocessing system. The highly concentrated regenerative cells were subsequently suspended in 40ml of a proprietary medium and then intra-dermally injected in the affected areas of the scalp. Each injection had 0.1ml of suspended cells for every 0.5cm diameter of the scalp.

The procedures were conducted with informed patient consent and the patients reported to the Company that there were no adverse events from the therapy.

Liberty is presenting and documenting these initial cases - in collaboration with medical professionals and researchers -- for further review, analysis, and clinical application to advance the use of autologous adipose stem cells in the treatment of hair loss alopecia.

The Company invites researchers and clinical specialists interested in autologous adipose stem cell for hair loss alopecia to contact Liberty Biopharma Inc.

Cautionary Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "likely", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that the Company may not successfully transition to a clinical stage company and successfully execute its development and commercialization activities. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company. Readers are cautioned that the above list of risk factors is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

For further information, please contact:

Liberty Biopharma Inc.

Alan Tam, CPA, CA

Chief Financial Officer

Telephone: (604) 604-377-7575

All Posts
×

Almost done…

We just sent you an email. Please click the link in the email to confirm your subscription!

OKSubscriptions powered by Strikingly